Skip to main content

NEWSROOM

Check out our news releases and see coverage of CND in the media.

On Our Radar
May 22, 2024

Gene-Pesticide Interaction May Increase Risk of Parkinson’s

Genetic mutations and exposure to pesticides have both been identified as risk factors for the…
On Our Radar
May 16, 2024

A Phase 2 Study Suggests Diabetes Treatment May Slow Progression of Motor Symptoms in Parkinson’s Disease

A study published last month in the New England Journal of Medicine evaluated lixisenatide, a…
On Our Radar
May 8, 2024

Tandem Cycling May Improve Health of Patients with Parkinson’s and Their Care Partners

A recent study showed that exercise may be helpful not only for patients with Parkinson’s…
CND In the News
April 30, 2024

A Roundup of JAMA Publication Coverage

The Synuclein-One Study has garnered a tremendous amount of interest since results were published in…
News Release
April 12, 2024

CND Life Sciences to Highlight Momentum of Skin Biopsy Diagnostic Tool for Parkinson’s Disease and Related Disorders at the American Academy of Neurology 2024 Annual Meeting

Synuclein-One Study plenary session on Monday, April 15 at 9:15 a.m. MT will report the…
News Release
March 20, 2024

Breakthrough Results of NIH-Sponsored Study of Syn-One Test® as a Skin-Based Diagnostic Tool for Parkinson’s Disease and Related Disorders Published in the Journal of the American Medical Association

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests…
News Release
March 5, 2024

CND Life Sciences Partners with Visiopharm on Novel AI-Tool to Detect and Quantify Pathological Alpha-Synuclein in Cutaneous Nerves

March 5, 2024 – Scottsdale, Ariz – CND Life Sciences (CND), a medical technology company…
On Our Radar
February 29, 2024

Seven Molecules Identified as Potential Treatments for Familial Parkinson’s

Conscience, a Canadian nonprofit biotech company, announced last month that seven molecules had been identified…
On Our Radar
February 19, 2024

Alterity Therapeutics to Continue Phase 2 Study of ATH434 in Multiple System Atrophy

After a prespecified review by an independent Data Monitoring Committee (DMC) found no safety concerns,…
On Our Radar
January 24, 2024

Genetic Mutation Reduces Risk of Parkinson’s Disease by Half

Researchers at the University of Southern California Leonard Davis School of Gerontology announced last week…
On Our Radar
January 19, 2024

Robotic Exosuit Eliminates Gait Freezing in Man With Parkinson’s

Annovis Bio announced that it has completed the final patient study visit in its Phase…
CND In the News
December 26, 2023

Syn-One Test® Gets a Spotlight in Medscape’s Parkinson’s Highlights of 2023

A recent Medscape discussion between Dr. Kathrin LaFaver, a neurologist in Saratoga Springs, New York,…
On Our Radar
December 18, 2023

Final Study Visit Milestone Reached in Trial of Buntanetap for Parkinson’s

Annovis Bio announced that it has completed the final patient study visit in its Phase…
On Our Radar
December 12, 2023

First Patient Receives Experimental AC Immune Parkinson’s Vaccine

Switzerland-based biopharmaceutical company AC Immune has dosed the first patient with ACI-7104, an experimental vaccine…
On Our Radar
December 4, 2023

Parkinson’s Vaccine: Second Part of Phase 1 Study Results Reported

Biotechnology company Vaxxinity, whose focus is developing vaccines to treat chronic diseases, announced the results…
News Release
November 16, 2023

CND Life Sciences Wins Prestigious Award as it Drives Innovation in Neurodiagnostics Field

November 16, 2023 – Scottsdale, Ariz. – CND Life Sciences, a medical technology company pioneering…
CND In the News
November 14, 2023

Article About the Syn-One Test® Published in Medscape Features Section

← Back Article About the Syn-One Test® Published in Medscape Features Section An article titled…
CND In the News
October 30, 2023

Syn-One Test® Highlighted in ABC13 Story About Parkinson’s Support Group

The Syn-One Test from CND Life Sciences was recently featured in a story about a…
On Our Radar
September 27, 2023

Researchers Discover How Alpha-Synuclein May Form Toxic Aggregates

Lipids are thought to play an important role in the aggregation of alpha-synuclein and are…
On Our Radar
September 21, 2023

Gain Therapeutics To Begin Phase 1 Trial of GT-02287 for Parkinson’s

A recently published study in Neurology showed that higher levels of physical activity were associated…
On Our Radar
August 24, 2023

Negative Correlation Between Legume Consumption and Prodromal Parkinson’s Risk in Patients With REM Sleep Behavior Disorder

A recently published study in Neurology showed that higher levels of physical activity were associated…
On Our Radar
August 16, 2023

Physical Activity Associated with Lower Risk of Parkinson’s in Large Cohort Study of Women

A recently published study in Neurology showed that higher levels of physical activity were associated…
On Our Radar
July 18, 2023

Vaccine for Parkinson’s Disease Meets Primary Endpoints in Phase 1 Trial

Vaxxinity, Inc. announced that its investigational synthetic peptide vaccine for Parkinson’s, UB-312, met the primary…
On Our Radar
June 21, 2023

Enterin Inc. Receives FDA Green Light to Test ENT-01 in Patient with Multiple System Atrophy

Enterin Inc., a biopharmaceutical company based in Philadelphia, is aiming to become the first to…
News Release
June 16, 2023

CND Life Sciences Receives Accreditation from the College of American Pathologists

CND Life Sciences, a medical technology company pioneering the development of skin-based tests to help…
CND In the News
May 18, 2023

A Roundup of Syn-One Study Results Coverage from AAN 2023

Topline results from the Synuclein-One Study, presented at the American Academy of Neurology Annual Meeting…
On Our Radar
May 11, 2023

Study Examines Diagnostic Utility of Syn-One Test® vs DaTscan

In a poster presented at the American Academy of Neurology 2023 Annual Meeting, researchers from…
On Our Radar
May 4, 2023

Skin Biopsy Using Immunofluorescence More Accurate Than Seed Amplification Assay in Detecting Alpha-Synuclein in RBD Patients

A study published this week in NJP Parkinson’s Disease compared two methods of detecting alpha-synuclein…
News Release
April 26, 2023

CND Life Sciences’ Syn-One Test® Detects Alpha-Synuclein in the Skin with High Sensitivity and Specificity in Patients with Parkinson’s Disease and Related Disorders

CND Life Sciences, a medical technology company pioneering the development of cutaneous neurodiagnostics, today announced…
CND In the News
April 17, 2023

News Outlets Take Note of Major Developments at CND Life Sciences

The last two weeks brought important milestones for CND Life Sciences, and several news outlets…
CND In the News
April 12, 2023

Rhode Island Man Grateful for Syn-One Test® in Aiding the Diagnosis of Parkinson’s Disease

WJAR news reported last month about a Pawtucket, Rhode Island man, Roger Miller, who began…
News Release
April 6, 2023

CND Life Sciences Closes Series Seed 3 Round, Reaches $12.5 Million in Total Equity Raised

CND raised an additional $1 million in venture financing from Top Corner Capital
News Release
March 30, 2023

Cutting Edge Medical Technology Company CND Life Sciences Announces Grand Opening of Global Headquarters and Laboratories in Scottsdale

Company Focuses on Innovative Diagnosis and Treatment of Neurodegenerative Diseases
News Release
March 22, 2023

CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative Diseases

Agreement with Beth Israel Deaconess Medical Center Solidifies Important Technology for CND’s Syn-One Test® and…
On Our Radar
March 6, 2023

Non-Surgical Ultrasound Procedure Improves Parkinson’s Motor Symptoms

Research published last month in the New England Journal of Medicine demonstrated that a focused…
On Our Radar
February 24, 2023

Neuron Replacement Therapy for Parkinson’s to Advance to Clinical Testing

San Diego-based Ryne Biotechnology announced last week that it has received a $4 million Clinical…
CND In the News
February 13, 2023

Syn-One Test® Provides Much-Needed Answers for Georgia Man

Georgia Public Broadcasting featured a story this week about how the Syn-One Test helped Dr.…
On Our Radar
February 7, 2023

KM-819 for the Treatment of Parkinson’s Disease Demonstrates Favorable Safety Profile in Healthy Adults

The California-based drug development company FAScinate Therapeutics, Inc. announced positive results from the first part…
On Our Radar
January 31, 2023

FDA Lifts Hold on IkT-148009 for Parkinson’s Disease

The FDA announced that it will lift the full Clinical Hold on IkT-148009, a c-Abl…
On Our Radar
January 24, 2023

Ambroxol Moves Into Phase 3 Trial for Parkinson’s Disease

Ambroxol, the active ingredient in cough syrup, is set to enter a Phase 3 clinical…
On Our Radar
January 17, 2023

Alpha-Synuclein Aggregates Shown to Occur Early in Inherited Forms of Parkinson’s Disease

Previous research has demonstrated that mutations in the SCNA gene, a gene responsible for the…
News Release
December 23, 2022

State of Arizona Commits Support for CND Life Sciences to Launch Groundbreaking Digital Biosignatures Lab for Neurodegenerative Diseases

CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of…
On Our Radar
December 20, 2022

New Study Shows Incidence of Parkinson’s Significantly Higher Than Previously Estimated

Previous estimates of the incidence of Parkinson’s disease have varied for reasons that are not…
CND In the News
December 8, 2022

Featured on WFSB News in Hartford

Dr. Toni De Marcaida, Medical Director of Hartford Healthcare's Chase Family Movement Disorders Center in…
On Our Radar
November 16, 2022

Potential Parkinson’s Treatment Well-Tolerated in Phase 1 Trial

1ST Biotherapeutics, Inc., announced positive results from a Phase 1 trial of FB-101, an investigational…
On Our Radar
November 9, 2022

Patients May Show Signs of Parkinson’s as Early as Nine Years Before Diagnosis

New research published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association last month…
News Release
November 3, 2022

CND Life Sciences Partners with Soleo Health to Broaden the Awareness and Availability of CND’s Cutaneous Neurodiagnostic Tests

Collaboration Focuses on CND’s Groundbreaking Syn-One Test® that Aids in the Diagnosis of Parkinson’s Disease…
News Release
October 6, 2022

CND Life Sciences Awarded Third NIH SBIR Grant to Study the Syn-One Test® in Patients Diagnosed with REM Sleep Behavior Disorder (RBD)

Grant Supports the Evaluation of CND’s Skin Biopsy Test to Identity Early Signs of Parkinson’s…
On Our Radar
September 14, 2022

Irisin Hormone Shows Positive Results in Mouse Model of Parkinson’s

Based on previous work demonstrating the positive effects of exercise on symptoms of Parkinson’s disease,…
On Our Radar
August 31, 2022

Seelos Therapeutics Receives Grant to Study CRISPR-Based Treatment for Parkinson’s and Lewy Body Dementia

Seelos Therapeutics announced it has received a grant from the Michael J. Fox Foundation for…
On Our Radar
August 18, 2022

Specific Gene Mutations Linked to Survival Time in Parkinson’s Disease

New research presented at the European Academy of Neurology (EAN) 2022 Congress has revealed a…
CND In the News
August 10, 2022

Dr. Levine Interviewed on Lewy Body Roller Coaster Podcast

Todd Levine, MD, Chief Medical Officer and Co-Founder of CND Life Sciences was interviewed last…
On Our Radar
August 4, 2022

Biogen to Collaborate With Alectos Therapeutics on Potential Treatment for Parkinson’s Disease

Biogen and Alectos Therapeutics have announced that they will collaborate on the development of AL01811,…
CND In the News
July 11, 2022

CND Life Sciences Mentioned in CNN Story About Robin Williams

“It wasn’t until Robin’s autopsy that we got an accurate diagnosis,” explains Susan Schneider Williams,…
On Our Radar
July 5, 2022

Synuclein Antibodies Not a Reliable Biomarker for Parkinson’s

Previous research has examined whether levels of alpha-synuclein autoantibodies (α-syn AAb) differ between patients with…
On Our Radar
May 26, 2022

Cutaneous Alpha-Synuclein Shown to Differentiate Parkinson’s From Related Neurological Disorders

A primary challenge in the diagnosis of neurological disorders is differentiating between conditions that share…
News Release
May 18, 2022

CND Life Sciences Awarded NIH SBIR Grant to Study Novel Skin Biopsy Test for Dementias

CND Life Sciences, an innovative medical diagnostics company pioneering the detection, visualization, and quantification of…
CND In the News
May 16, 2022

Dr. Levine to Present at Controversies in Movement Disorders Event

Dr. Todd Levine, Chief Medical Officer and Co-Founder of CND Life Sciences will present as…
CND In the News
May 2, 2022

Syn-One Test® Featured on CN2 News South Carolina

In honor of national Parkinson’s month, CN2 news in Rock Hill, SC featured Memory &…
On Our Radar
April 1, 2022

Researchers Discover Genetic Signature in Patients With Parkinson’s

Researchers from La Jolla Institute for Immunology have discovered a genetic signature on the circulating…
News Release
March 24, 2022

CND Life Sciences Adds Two Accomplished Pathologists to Leadership Team

Will Advance the Company’s Technology Designed to Aid the Diagnosis of Parkinson’s Disease and Other…
News Release
February 1, 2022

CND Life Sciences Closes Series Seed 2 Round, Reaches $8 Million in Total Capital Raised

Strong market adoption of Syn-One Test™ to help clinicians diagnose Parkinson’s Disease and other neurological…
On Our Radar
January 19, 2022

First Patient With Parkinson’s Receives Alpha-Synuclein Vaccine in Phase 1 Study

Vaxxinity, a “purpose-driven biotechnology company committed to democratizing healthcare across the globe,” announced that it…
On Our Radar
December 28, 2021

AC Immune Awarded Two Grants for Research of Potentially Disease-Modifying Parkinson’s Treatments

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded two grants to AC…
On Our Radar
December 1, 2021

Tyrosine Kinase Inhibitor Shows Potential as Disease-Modifying Treatment for Parkinson’s

Boston- and Atlanta-based clinical-stage pharmaceutical company Inhibikase Therapeutics, Inc. published the biochemical rationale for potentially…
On Our Radar
November 22, 2021

Phase 1b Results Reported for Potentially First-in-Class Parkinson’s Treatment

Boston-based biopharma company Yumanity Therapeutics announced last week that its drug candidate, YTX-7739, met its…
On Our Radar
November 17, 2021

Monoclonal Antibody for Parkinson’s Disease Moves to Phase I Clinical Testing

A monoclonal antibody that binds to alpha-synuclein is advancing into a clinical trial after showing…
On Our Radar
October 27, 2021

New Research Identifies Potential Pathway for Stopping Spread of Alpha-Synuclein

A hallmark of Parkinson’s disease is the presence of Lewy bodies—abnormal clumps of protein primarily…
On Our Radar
October 20, 2021

Molecule Shows Potential to Slow Production of Alpha-Synuclein

Researchers at the University of Utah tested more than 150,000 compounds in search of candidates…
On Our Radar
October 12, 2021

Researchers Discover Potential Link Between Alpha-Synuclein and X-Linked Dystonia-Parkinsonism

In a new paper published in Movement Disorders, researchers for the first time established a…
On Our Radar
September 28, 2021

Gain Therapeutics Identifies Compounds for Potential Treatment of Parkinson’s and Gaucher Disease

Biotech company Gain Therapeutics, Inc. announced positive results from an initial study of two Structurally…
On Our Radar
September 15, 2021

Researchers Discover New Pathogenic Pathway in Parkinson’s Disease

Previous research has demonstrated that alpha-synuclein can damage mitochondria, the organelle responsible for cellular energy…
News Release
September 7, 2021

CND Life Sciences Adds Biopharma Veteran To Its Board

Enrique Carrazana, MD Brings Deep Expertise in Neuroscience and the Life Sciences Industry to Support…
On Our Radar
September 1, 2021

Annovis Bio Completes Dose-Response Study of ANVS401 in Parkinson’s Disease

Annovis Bio, Inc., has completed a two-part Phase 2a study of ANVS401 (also known as…
On Our Radar
August 12, 2021

Alterity Therapeutics Publishes Pre-Clinical Data for ATH434 in Multiple System Atrophy

There are currently no treatments available for multiple system atrophy (MSA), a rare and fatal…
CND In the News
August 2, 2021

Marcus Neuroscience Institute Offers Syn-One Test™ to Patients

Specialized neurologic and neurosurgical care center Marcus Neuroscience Institute, part of Baptist Health South Florida,…
On Our Radar
July 23, 2021

Epigenome-Editing Therapy Reduces Alpha-Synuclein Levels in Mice

Biopharmaceutical company Seelos Therapeutics in conjunction with researchers at Duke University School of Medicine announced…
On Our Radar
July 19, 2021

FDA Narrows Indication for Biogen’s Aduhelm in Alzheimer’s Disease

News came last week that after the controversial early-June approval of Aduhelm, the first new…
CND In the News
June 16, 2021

Dr. Todd Levine Interviewed on Arizona ABC15 About New Alzheimer’s Treatment

Aducanumab, the first treatment for Alzheimer’s disease to be approved in nearly two decades, has…
CND In the News
June 8, 2021

Dr. Todd Levine Highlights Role of the Syn-One Test™ in Clinical Research on 17 Branches Podcast

Dr. Todd Levine, Co-Founder and Chief Medical Officer of CND Life Sciences made his podcast…
On Our Radar
June 2, 2021

Researchers Identify One Way Alpha-Synuclein Spreads Throughout the Brain in Parkinson’s Disease

Parkinson’s disease is caused by the accumulation of alpha-synuclein, a misfolded protein that interferes with…
On Our Radar
May 11, 2021

UCB Biopharma Releases Phase 1b Data for Synuclein-Targeting Therapy in Parkinson’s Disease

UCB presented data from a Phase 1b study of UCB0599, an oral compound that suppresses…
CND In the News
May 5, 2021

First Doctor to Perform Syn-One Test™ in Alabama Interviewed on ABC News

Dr. Timothy Prestley, Founder & Director of Novus Neurology & TMS in Tuscaloosa, Alabama, was…
On Our Radar
April 28, 2021

Aptinyx Restarts Study of Treatment for Cognitive Impairment in PD and DLB

Aptinyx, Inc. was forced to suspend its study of NYX-458—a treatment for cognitive impairment in…
News Release
April 22, 2021

CND Life Sciences Partners with FFF Enterprises and NuFactor

Strategic Collaboration Educates Neurology Community About Syn-One Test™
CND In the News
March 31, 2021

Phoenix Business Journal Covers $2.4 Million Seed Funding, Profiles CND

CND Life Sciences continues to build its presence as an exciting medical technology start-up. Phoenix…
News Release
March 23, 2021

CND Life Sciences Closes Series Seed Funding Round

Innovators of the Syn-One Test™ Building Market Presence and Infrastructure
On Our Radar
March 4, 2021

Researchers Identify Five Genes Linked to Lewy Body Dementia

By identifying potential genetic causes of Lewy body dementia (LBD), researchers hope to gain a…
On Our Radar
March 1, 2021

New Research Furthers Understanding of the Role of Alpha-Synuclein, a Key Protein in Parkinson’s Disease

Although some symptoms of Parkinson’s disease (PD) can be controlled by medication, the hope of…
On Our Radar
February 16, 2021

Alterity Therapeutics Receives Grant to Study ATH434 in Parkinson’s Disease

Alterity Therapeutics announced that it has received a second grant from The Michael J. Fox…
On Our Radar
February 4, 2021

Researchers Identify Proteins With Potential to Treat Parkinson’s Disease

Parkinson’s is a complicated neurological disorder that researchers are continuously working to understand. However, a…
News Release
January 7, 2021

CND Life Sciences to Present at Biotech Showcase Investor Conference

Poised for Growth After Successfully Launching First Skin-Based Test for Parkinson's
On Our Radar
January 4, 2021

German Biotech Initiates Phase 1b Clinical Trial of Synucleinopathy Treatment

MODAG, a German biotechnology company, announced that it would begin an in-patient clinical trial of anle138b,…
CND In the News
December 22, 2020

Dr. Todd Levine Talks With Medical World News About the Potential of the Syn-One Test™ to Impact Patients’ Care

Todd Levine, MD, Co-Founder and Chief Medical Officer of CND Life Sciences was recently interviewed…
On Our Radar
December 8, 2020

Eisai Co. and Wren Therapeutics Collaborate to Target Alpha-Synuclein

The two companies announced an exclusive collaboration agreement that aims to develop treatments that target…
CND In the News
November 16, 2020

CND Life Sciences CEO Rick Morello Discusses Syn-One Test™ on the Price of Business Radio Show

Rick Morello spoke with Kevin Price, host of the Price of Business Radio Show, about…
CND In the News
November 16, 2020

News Outlets Taking Notice of CND Life Sciences’ NIH Grant Award

News of CND Life Sciences’ $2.4 million grant from the National Institutes of Health is…
CND In the News
November 4, 2020

Phoenix Business Journal Highlights CND Life Sciences’ Plans to Expand, Hire More Staff

Hiring slowed in the healthcare sector across the Valley during the coronavirus pandemic, but that…
On Our Radar
October 27, 2020

Prothena and Roche moving ahead with alpha-synuclein-targeting drug for Parkinson’s disease

Good news in the world of drug development and future treatments for synucleinopathies...

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our free Skin Biopsy Test Kit, simply collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit